Follitropin beta

When ATH:
G03GA06

Pharmacological action.
Estrogenpodobnoe.

Application.

Infertility in women, due to hypothalamic-pituitary disorders (hypogonadotropic hypogonadism), inadequate follicular maturation (failure of the corpus luteum); polycystic ovary syndrome, refractory to treatment with clomiphene citrate, induction of superovulation (in vitro fertilization, embryo transfer, the transfer of gametes into the fallopian tube, intratsitoplazmaticheskaya inaektsiya sperm).

Contraindications.

Hypersensitivity, hypertrophy, or ovarian cysts, uterine bleeding of unknown etiology, tumors of the pituitary gland and the hypothalamus, uterus, ovary, Breast, fibroids and uterine fibroids, genital malformations, incompatible with pregnancy, primary ovarian failure, ekstragenital'nye endocrinopathies, caused by tumors of the thyroid and adrenal glands, thyroid disease, adrenal and pituitary, expressed human liver and kidneys, pregnancy, lactation.

Side effects.

Ovarian hyperstimulation syndrome (lower abdominal pain, nausea, diarrhea, the development of ovarian cysts, ascites, gidrotoraks, thromboembolism, oligurija, gipotenziya), Multiple or ectopic pregnancy, fever, artralgii, breast pain, skin rash, hives, possible formation of antibodies (prolonged use), redness at the injection site.

Cooperation.

Clomiphene citrate may increase the severity of ovarian stimulation. Sharing agonist of gonadotropin-releasing hormone requires increasing the dose. Pharmaceutical incompatible (do not mix in the same syringe) Happy Birthday. Drug.

Dosing and Administration.

B / (slowly), n / a. При бесплодии начальная доза — 50–75 МЕ ежедневно в течение 7 days, in the absence of a response of the ovaries gradually increase the dose (when the estradiol levels of 300-900 pg / mL cancel). During the in vitro fertilization in the first 4 дня назначают по 100–200 МЕ, затем — в среднем по 75–350 МЕ ежедневно в течение 1–2 нед.

Precautions.

The treatment requires daily hormonal and ultrasound monitoring of the state of the developing follicles (ovarian response can be assessed by cervical index). When the threat of ovarian hyperstimulation syndrome treatment is stopped. It is recommended to constantly change the injection site.